Inhibitors that target various cellular signaling pathways offer a strategic approach to attenuating the activity of C14orf165. These compounds can intervene at pivotal points in signaling cascades, such as kinase activity, which is crucial for the phosphorylation and subsequent activation of many proteins, including C14orf165. By inhibiting kinases, these molecules prevent the phosphorylation that would typically result in the activation of C14orf165, thereby diminishing its functional activity within the cell. Furthermore, the interruption of the PI3K pathway, a critical signaling route that modulates cell growth and survival, can also lead to a decrease in the activation of downstream targets, potentially including C14orf165. This inhibition can result in a reduction of the cellular processes that C14orf165 may facilitate.
Additionally, the manipulation of proteasome function is another method through which the activity of C14orf165 may be indirectly inhibited. Proteasome inhibitors can lead to the buildup of ubiquitinated proteins, which might include C14orf165, affecting its stability and turnover rate. The accumulation of such ubiquitinated proteins could trigger a cellular response that alters the functionality of C14orf165. Meanwhile, compounds that specifically inhibit the MAPK/ERK and JNK pathways can thwart the signaling processes that may lead to the activation or regulation of C14orf165.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can suppress various kinases that may phosphorylate C14orf165, leading to its inactivation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that could reduce the phosphorylation status of downstream proteins, including C14orf165, thus inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can decrease the activation of pathways that phosphorylate C14orf165, resulting in its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can diminish signaling pathways involved in the activation of C14orf165. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that can lead to reduced MAPK/ERK pathway activity, leading to decreased activation of C14orf165. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can prevent the activation of MAPKs which may be upstream regulators of C14orf165. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could block the JNK signaling pathway and thereby inhibit the function of C14orf165. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
A RAF kinase inhibitor which may halt the RAF/MEK/ERK signaling cascade affecting the activity of C14orf165. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor which may affect signaling pathways involved in the regulation of C14orf165 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, affecting the stability of C14orf165. | ||||||